S&P 500$7,499.36+0.80%
NASDAQ$26,040.00-0.66%
GOLD$4,170.25+1.15%
VIX18.50-2.10%
NEM$97.04+0.52%
LLY$1,213.91+1.20%
AVGO$360.45+0.36%
UTHR$555.91+1.60%
10-YR UST4.52%+0.02%
EUR/USD1.0872-0.12%
OIL (WTI)$72.30-0.40%
S&P 500$7,499.36+0.80%
NASDAQ$26,040.00-0.66%
GOLD$4,170.25+1.15%
VIX18.50-2.10%
NEM$97.04+0.52%
LLY$1,213.91+1.20%
AVGO$360.45+0.36%
UTHR$555.91+1.60%
10-YR UST4.52%+0.02%
EUR/USD1.0872-0.12%
OIL (WTI)$72.30-0.40%
📋
Signal Date
July 6, 2026
⏱️
Report Time (Brussels)
19:40 CEST
🎯
Signals Active
4 — BUY
Price Refresh
Jul 3 close

🧠 HMM Market Regime

Hidden Markov Model
BULL REGIME
Current market state — HMM 3-state model
Bull Probability 72%Bear Risk 28%
BearishNeutralBullish
Regime transition probability to bearish state = 28% — below the 60% trigger threshold. All four signals remain statistically valid in current regime.
S&P 500 Q2 2026+14.9%
Nasdaq Q2 2026+21.4%
VIX Level18.50
Bear Transition28% — OK
Gold YoY+25%

🎯 Active Buy Signals — July 6, 2026

4 Signals
TickerCompanySector / Theme PriceAnalyst TargetQuant Signal Exit CheckKelly f*Conflict (MAR 20)
NEM Newmont Corp. 🥇 Gold Cycle $97.04 $130.60 +34.6% 🟢 BUY 🟢 HOLD f*=0.46 → 16% ✅ Publisher holds
LLY Eli Lilly & Co. 💊 GLP-1 $1,213.91 $1,350.00 +11.2% 🟢 BUY 🟢 HOLD f*=0.34 → 12% ✅ Publisher holds
AVGO Broadcom Inc. ⚙️ Custom Silicon $360.45 $501.58 +39.2% 🟢 BUY 🟢 HOLD f*=0.39 → 14% ✅ Publisher holds
UTHR United Therapeutics 🫁 Pulm. Hypert. $555.91 $611.64 +10.0% 🟢 BUY 🟢 HOLD f*=0.41 → 14% ✅ Publisher holds

⭐ Detailed Signal Cards

Full Quant Analysis
NEM
Newmont Corporation
🥇 Gold / Materials World's #1 Gold Miner NYSE: NEM
$97.04
Jul 3 close  ·  Market cap ~$77B
🟢  BUY SIGNAL
📈 Technical Analysis
200-Day Moving Avg$103.10 ⚠️ Below
52-Week Range$62.44 – $59.17 ATH?
RSI (14-day)~70.6 — Near Overbought
MACD Signal🟢 Positive (since Jun 16)
8-Week Trend+8.19% — Uptrend Active
Volume SignalAbove avg — Accumulation
Support Zone$88 – $91
Resistance Zone$103 – $108
📉 Fundamental Analysis
Q1 Realized Gold Price$4,900/oz (Record)
Q1 AISC (All-In Cost)$1,029/oz
Gross Margin/oz~$3,871 — Record
Q1 Output~1.3M oz (Record)
Gold-AISC Spread+276%
Trailing P/E~12x
EV/EBITDA~7.2x
Dividend Yield~2.2%
🔍 Intrinsic Value Check (Buffett/Munger)
Net Income (ann.)~$6.4B
+ D&A (ann.)~$2.8B
− CapEx (ann.)−$2.4B
Owner Earnings~$6.8B / yr
Buffett DCF Value$145 – $175/sh
Current Price$97.04
Margin of Safety✅ 33–44%
Munger Moat Score
★★★★★ WIDE MOAT
World's largest gold miner · 30+ yr mine life · Full pricing power via gold parity · Irreplaceable assets
💡 ATTRACTIVE — Market price ≤ 70% of intrinsic value ✅ CONFIRMED
🎯 Quantitative Signal Model
Z-score EPS Revisions+1.80 ✅ (>+1.5)
Kelly f*0.457 (p=0.68, b=1.44)
Fractional Kelly (35%)16.0% of portfolio
PEG Ratio0.61 — BUY (< 1.0) ✅
HMM Bear Probability28% — Below 60% ✅
Analyst Upside Consensus+43.7%
Gold Macro Target (JPM)$6,000 Q4 2026
Expected Return E[R]+38.4% (weighted)
🔴 Probabilistic Exit Signal Check
Z-score EPS revision decay (<−1.0)NOT TRIGGERED
HMM Regime shift (>60% bear)NOT TRIGGERED
Kelly Fraction collapse (f* < 0.05)NOT TRIGGERED
Momentum reversal (RSI <50 + MACD neg.)NOT TRIGGERED
Mean reversion exhaustion (>2σ above mean)MONITOR
🟢 HOLD — 0 signals triggered
🎯 Purchase Strategy — 3 Tranches
T1Current zone — Gold momentum + MoS confirmed$93–$98
T2Pullback to 50-day MA — add on dip$85–$90
T3Deep dip to strong support — reload$78–$82
Stop-Loss (ATR ×2.5 + 10% draw)$87.50
Base
$115
+18.5%
Bull
$145
+49.4%
Stretch
$175
+80.3%
Time Horizon12–24 months
Risk Score6 / 10
LLY
Eli Lilly and Company
💊 Pharma / GLP-1 Obesity · Diabetes · Oncology NYSE: LLY
$1,213.91
Jul 3 close  ·  Market cap ~$1.15T
🟢  BUY SIGNAL
📈 Technical Analysis
200-Day Moving Avg~$985 — Well above ✅
52-Week Range$725 – $1,238
RSI (14-day)~58 — Healthy
MACD Signal🟢 Positive crossover
8-Week Trend+12.2% — Strong uptrend
Volume SignalInstitutional accumulation
Support Zone$1,140 – $1,160
Resistance Zone$1,238 – $1,260
📉 Fundamental Analysis
Q1 2026 Revenue~$12.7B (+45% YoY)
GLP-1 Revenue (Mounjaro+Zepbound)~$7.5B Q1
Non-GAAP EPS (Q1)$3.34 (est. +55%)
Gross Margin~81%
Free Cash Flow (ann.)~$9.5B
Forward P/E~38x (growth premium)
PEG Ratio0.82 — BUY ✅
Net Cash / DebtNet debt ~$14B
🔍 Intrinsic Value Check (Buffett/Munger)
Net Income (ann., adj.)~$8.1B
+ D&A (ann.)~$3.0B
− CapEx (ann.)−$3.5B
Owner Earnings~$7.6B / yr ($8.09/sh)
Buffett DCF Value$1,050 – $1,350/sh
Current Price$1,213.91
Margin of Safety~0–10% — Marginal
Munger Moat Score
★★★★☆ WIDE MOAT
GLP-1 patent protection through 2031+ · Manufacturing scale-up moat · Regulatory approval pipeline lead · Pricing power in obesity therapy
⚠️ MoS < 30% — Growth premium applies. Structurally bullish thesis intact. Not a classic Buffett value buy; a Munger-style quality-at-fair-value.
🎯 Quantitative Signal Model
Z-score EPS Revisions+2.10 ✅ (>+1.5)
Kelly f*0.335 (p=0.65, b=1.11)
Fractional Kelly (35%)11.7% of portfolio
PEG Ratio0.82 — BUY ✅
HMM Bear Probability28% — Below 60% ✅
Analyst Consensus Target$1,350 (Cantor Fitz.)
GLP-1 Market 2030E$100B+
Expected Return E[R]+22.6% (weighted)
🔴 Probabilistic Exit Signal Check
Z-score EPS revision decay (<−1.0)NOT TRIGGERED
HMM Regime shift (>60% bear)NOT TRIGGERED
Kelly Fraction collapse (f* < 0.05)NOT TRIGGERED
Momentum reversal (RSI <50 + MACD neg.)NOT TRIGGERED
Mean reversion exhaustion (>2σ above mean)NOT TRIGGERED
🟢 HOLD — 0 signals triggered
🎯 Purchase Strategy — 3 Tranches
T1Current zone — GLP-1 momentum + Z-score signal$1,190–$1,220
T2Pullback to 50-day MA support$1,100–$1,140
T3Deep dip — earnings or trial data miss$980–$1,020
Stop-Loss (ATR ×2.5 + 10% draw)$1,090
Base
$1,350
+11.2%
Bull
$1,550
+27.7%
Stretch
$1,800
+48.3%
Time Horizon18–36 months
Risk Score5 / 10
AVGO
Broadcom Inc.
⚙️ Semiconductors / AI Silicon Custom ASIC · VMware · AI Infra NASDAQ: AVGO
$360.45
Jul 2 close  ·  Market cap ~$1.52T
🟢  BUY SIGNAL
📈 Technical Analysis
200-Day Moving Avg~$340 — Above ✅
52-Week Range$269.58 – $495.00
% From ATH−27.2% — Dip opportunity
RSI (14-day)~62 — Healthy
MACD Signal🟢 Positive momentum
8-Week Trend+4.8%
Support Zone$330 – $345
Resistance Zone$380 – $400
📉 Fundamental Analysis
FY2026E Revenue (ann.)~$75B (+42% YoY)
AI Custom Silicon Rev.~$20B+ (hypercaler ASICs)
Non-GAAP Operating Margin~62%
Non-GAAP FCF~$42B annualized
Forward P/E (non-GAAP)~34x
PEG Ratio0.88 — BUY ✅
EV/EBITDA~28x (AI premium)
VMware Integration Synergies$8.5B annualized
🔍 Intrinsic Value Check (Buffett/Munger)
Net Income GAAP (ann.)~$5.9B
+ D&A (excl. VMware goodwill)~$1.1B
− CapEx (ann.)−$0.5B
Owner Earnings (adj.)~$15.4B / yr ($3.67/sh)
Buffett DCF — Base$300 – $380/sh
Buffett DCF — Non-GAAP adj.$480 – $620/sh
Current Price$360.45
Margin of Safety~5–25% (adj. basis)
Munger Moat Score
★★★★☆ WIDE MOAT
Custom silicon monopoly for hyperscalers (Google, Meta, Apple) · VMware lock-in (15,000+ enterprise customers) · 3-5 yr custom ASIC design cycles create switching costs
⚠️ MoS confirmed only on non-GAAP adjusted basis. GAAP MoS marginal due to VMware goodwill amortization. AI growth optionality partially compensates.
🎯 Quantitative Signal Model
Z-score EPS Revisions+1.60 ✅ (>+1.5)
Kelly f*0.390 (p=0.66, b=1.39)
Fractional Kelly (35%)13.7% of portfolio
PEG Ratio0.88 — BUY ✅
HMM Bear Probability28% — Below 60% ✅
Analyst Consensus Target$501.58 (+39.2%)
AI Custom Silicon TAM 2027E$200B+
Expected Return E[R]+32.8% (weighted)
🔴 Probabilistic Exit Signal Check
Z-score EPS revision decay (<−1.0)NOT TRIGGERED
HMM Regime shift (>60% bear)NOT TRIGGERED
Kelly Fraction collapse (f* < 0.05)NOT TRIGGERED
Momentum reversal (RSI <50 + MACD neg.)NOT TRIGGERED
Mean reversion exhaustion (>2σ above mean)NOT TRIGGERED
🟢 HOLD — 0 signals triggered
🎯 Purchase Strategy — 3 Tranches
T1Current zone — AI silicon momentum confirmed$350–$370
T2Dip to 200-day MA — volume spike trigger$330–$345
T3Deep correction — sector-wide AI reset$295–$315
Stop-Loss (ATR ×2.5 + 10% draw)$324
Base
$450
+24.8%
Bull
$550
+52.6%
Stretch
$650
+80.3%
Time Horizon12–24 months
Risk Score5 / 10
UTHR
United Therapeutics Corporation
🫁 Biotech / Rare Disease Pulm. Hypertension · Xenotransplant NASDAQ: UTHR
$555.91
Jul 4 close  ·  Market cap ~$23.6B
🟢  BUY SIGNAL
📈 Technical Analysis
200-Day Moving Avg~$510 — Above ✅
52-Week Range$422 – $587
% From 52W High−5.3% — Near highs
RSI (14-day)~55 — Healthy
MACD Signal🟢 Positive momentum
8-Week Trend+6.4%
Support Zone$520 – $535
Resistance Zone$580 – $600
📉 Fundamental Analysis
Trailing P/E20.52x — Low for biotech
EPS (TTM)$27.09/share
Net Income (ann.)~$1.15B
Revenue Growth YoY~+10%
Free Cash Flow~$1.0B (FCF yield 4.2%)
Net Cash Position~$2.1B net cash ✅
Gross Margin~79%
YTD Return+12.6%
🔍 Intrinsic Value Check (Buffett/Munger)
Net Income (ann.)~$1.15B
+ D&A (ann.)~$0.25B
− CapEx (ann.)−$0.30B
Owner Earnings~$1.10B / yr ($25.88/sh)
Buffett DCF Value$780 – $930/sh
Current Price$555.91
Margin of Safety✅ 29–40%
Munger Moat Score
★★★★☆ WIDE MOAT
PAH market dominance (Tyvaso/Remodulin/Unituxin) · FDA-approved xenotransplant pipeline (first-in-world) · Small float = minimal dilution risk · No patent cliff near-term
💡 ATTRACTIVE — Market price ≤ 70% of intrinsic value ✅ CONFIRMED (DCF base: $780/sh)
🎯 Quantitative Signal Model
Z-score EPS Revisions+1.70 ✅ (>+1.5)
Kelly f*0.410 (p=0.67, b=1.10)
Fractional Kelly (35%)14.4% of portfolio
PEG Ratio0.76 — BUY ✅
HMM Bear Probability28% — Below 60% ✅
Analyst Consensus Target$611.64 (+10.0%)
Xenotransplant Pipeline Value$200–500B TAM
Expected Return E[R]+28.5% (weighted)
🔴 Probabilistic Exit Signal Check
Z-score EPS revision decay (<−1.0)NOT TRIGGERED
HMM Regime shift (>60% bear)NOT TRIGGERED
Kelly Fraction collapse (f* < 0.05)NOT TRIGGERED
Momentum reversal (RSI <50 + MACD neg.)NOT TRIGGERED
Mean reversion exhaustion (>2σ above mean)NOT TRIGGERED
🟢 HOLD — 0 signals triggered
🎯 Purchase Strategy — 3 Tranches
T1Current zone — MoS confirmed + PAH pipeline strong$545–$565
T2Pullback to 50-day MA — add on dip$510–$525
T3Deep dip — biotech sector selloff$460–$475
Stop-Loss (ATR ×2.5 + 10% draw)$500
Base
$611
+9.9%
Bull
$720
+29.5%
Stretch
$850
+52.9%
Time Horizon12–30 months
Risk Score4 / 10

📐 Quantitative Framework — Signal Rules

PC-QSM Model

🎲 Kelly Criterion

Position sizing derived from win probability p and estimated payoff ratio b (analyst target / entry price). A fractional Kelly α = 0.35 is applied to account for model uncertainty.

f* = (p × b − (1−p)) / b
Position = f* × α × portfolio
NEM — f*0.457 → 16%
LLY — f*0.335 → 12%
AVGO — f*0.390 → 14%
UTHR — f*0.410 → 14%
Fractional α0.35 (conservative)

📊 Z-Score EPS Revisions

Buy signal triggered when Z-score of analyst EPS revisions exceeds +1.5. Exit when Z-score drops below −1.0. All four signals are in positive revision territory.

Z = (EPS_rev − μ_rev) / σ_rev
Buy if Z > +1.5 | Exit if Z < −1.0
NEM Z-score+1.80 ✅
LLY Z-score+2.10 ✅
AVGO Z-score+1.60 ✅
UTHR Z-score+1.70 ✅

🧠 HMM Regime Detection

3-state Hidden Markov Model (Bull / Neutral / Bear). Signals deployed only when bear transition probability < 60%. Current bull probability = 72%. All signals valid.

P(Bearish | data_t) < 0.60 → deploy signal
Transition matrix estimated on 20yr S&P 500 data
Current regimeBULL 🟢
Bull probability72%
Bear transition28%
Signal validityALL 4 VALID ✅

⚙️ Signal Rules Checklist

All four signals pass the full rule set. Signals are deployed only when all conditions are simultaneously met.

Z-score entry threshold|Z| > 1.5
Kelly min thresholdf* > 0.05
HMM bear limit< 60%
RSI entry range30–75
Max drawdown stop−10% rule
PEG signalPEG < 1.0
Fractional Kelly α0.25–0.50

⚖️ Full Legal Disclaimer

Juridisch geauditeerde disclaimer · Legal audited disclaimer · Avertissement légalement audité
Belgisch recht / EU-recht / US federal law  ·  Juli / July / Juillet 2026

Wat u hier krijgt — en wat niet

Dit is een signaalabonnement. Geen advies. Het verschil is niet semantisch — het is juridisch bepalend, en het is precies de reden waarom dit platform legaal opereert zonder enige vergunning van de FSMA of een andere financiële toezichthouder.

Elke signal die The Purple Compounder publiceert, gaat op hetzelfde moment naar elke abonnee. Identiek. Zonder enige aanpassing aan uw persoonlijke financiële situatie, uw risicoprofiel, uw beleggingshorizon of uw vermogensdoelstellingen. Dat is geen tekortkoming. Dat is de opzet.

De juridische grondslag

🇧🇪 Belgisch en EU-recht

Beleggingsadvies — in de zin van de Europese Richtlijn 2014/65/EU (MiFID II), art. 4(1)(4), en de Belgische Wet van 25 oktober 2016 betreffende de toegang tot het beleggingsdienstenbedrijf (BS 18 november 2016) — is wettelijk gedefinieerd als een gepersonaliseerde aanbeveling aan een specifieke cliënt, rekening houdend met diens individuele omstandigheden.

Dat is hier niet het geval. Signals die via een distributiekanaal aan alle abonnees gelijktijdig worden bezorgd, vormen krachtens art. 9(2) van Gedelegeerde Verordening (EU) 2017/565 uitdrukkelijk geen persoonlijke aanbeveling. Zij vallen buiten de vergunningsplicht. The Purple Compounder is geen beleggingsonderneming, geen beleggingsadviseur en geen vermogensbeheerder in de zin van de toepasselijke wetgeving.

Geen FSMA-vergunning is vereist. Dat is niet een mening — het volgt rechtstreeks uit de wet.

🇺🇸 Amerikaans federaal recht — Investment Advisers Act of 1940

De signalen gepubliceerd door The Purple Compounder zijn vrijgesteld van registratie bij de SEC op grond van Section 202(a)(11)(D) van de Investment Advisers Act of 1940 (15 U.S.C. § 80b-2(a)(11)(D)), de zogenoemde publisher's exemption. De signalen worden generiek en gelijktijdig aan alle abonnees gepubliceerd, zonder personalisatie, en vormen een bona fide financiële publicatie van algemene en regelmatige circulatie, zoals bevestigd door het U.S. Supreme Court in Lowe v. SEC, 472 U.S. 181 (1985).

The Purple Compounder is niet geregistreerd bij de SEC als investment adviser, is geen geregistreerde broker-dealer, en verstrekt geen gepersonaliseerd beleggingsadvies. Niets in dit abonnement vormt beleggingsadvies in de zin van het federale of staatssecuritiesrecht van de VS. Abonnees in de VS zijn zelf verantwoordelijk voor hun lokale wettelijke vereisten.

Belangen en transparantie (MAR art. 20)

Verordening (EU) nr. 596/2014 (MAR), art. 20, de bijhorende Gedelegeerde Verordening (EU) 2016/958, en Section 206 van de Investment Advisers Act van 1940 verplichten iedere persoon die beleggingsaanbevelingen produceert of verspreidt om zijn belangenconflicten openbaar te maken en eerlijk te handelen.

The Purple Compounder houdt persoonlijk posities aan in dezelfde aandelen waarover signals worden gepubliceerd. Bij elk signaal — zonder uitzondering — wordt vermeld of de signaalopgever zelf een positie aanhoudt in het betrokken instrument op het moment van publicatie.

Huidige positieopenbaarmaking (Juli 6, 2026):

NEM — ✅ Publisher houdt positie aan
LLY — ✅ Publisher houdt positie aan
AVGO — ✅ Publisher houdt positie aan
UTHR — ✅ Publisher houdt positie aan

Ik koop wat ik publiceer. Dat vind ik een pluspunt, geen probleem. Maar u mag dat zelf beoordelen, met volledige informatie.

Risicowaarschuwing

Beleggen in aandelen en andere financiële instrumenten brengt risico's met zich mee. U kunt een deel van uw ingelegde kapitaal verliezen — of alles. Rendementen uit het verleden zijn geen betrouwbare indicator voor toekomstige resultaten. De signals zijn louter informatief. U neemt uw eigen beslissingen, met uw eigen geld. Twijfelt u? Raadpleeg een vergunde beleggingsadviseur of uw bank.

Uw keuze

Door te abonneren bevestigt u dat u begrijpt wat u afneemt: marktinformatie, geen advies op maat. U beslist zelfstandig of en hoe u handelt op basis van de gepubliceerde signals. Dat is uw recht — en uw verantwoordelijkheid.

Juridische verwijzingen

What You Receive Here — and What You Do Not

This is a signal subscription. Not advice. That distinction is not merely semantic — it is legally decisive, and it is precisely why this service operates lawfully without any licence from the FSMA or any other financial regulator.

Every signal published by The Purple Compounder is sent simultaneously to all subscribers. Identical. Without any adjustment for your personal financial situation, your risk profile, your investment horizon or your financial objectives. That is not a limitation. That is the design.

The Legal Basis

🇧🇪 Belgian and EU Law

Investment advice — within the meaning of European Directive 2014/65/EU (MiFID II), art. 4(1)(4), and the Belgian Law of 25 October 2016 on access to the investment services business (Belgian Official Gazette, 18 November 2016) — is legally defined as a personalised recommendation made to a specific client, based on consideration of that person's individual circumstances.

That is not what happens here. Signals distributed simultaneously through a distribution channel to all subscribers explicitly do not constitute a personal recommendation within the meaning of art. 9(2) of Commission Delegated Regulation (EU) 2017/565. They therefore fall outside the scope of the licence requirement. The Purple Compounder is not an investment firm, not an investment adviser and not a portfolio manager within the meaning of applicable law.

No FSMA licence is required. This is not an opinion — it follows directly from the law.

🇺🇸 United States Federal Law — Investment Advisers Act of 1940

The signals published by The Purple Compounder are exempt from registration with the SEC under Section 202(a)(11)(D) of the Investment Advisers Act of 1940 (15 U.S.C. § 80b-2(a)(11)(D)), the so-called publisher's exemption. The signals are published generically and simultaneously to all subscribers, without personalisation, and constitute a bona fide financial publication of general and regular circulation, as confirmed by the United States Supreme Court in Lowe v. SEC, 472 U.S. 181 (1985).

The Purple Compounder is not registered with the SEC as an investment adviser, is not a registered broker-dealer, and does not provide personalised investment advice. Nothing in this subscription constitutes investment advice within the meaning of federal or state securities law in the United States. Subscribers in the United States are solely responsible for their own local legal requirements.

Interests and Transparency (MAR art. 20)

Regulation (EU) No 596/2014 (MAR), art. 20, Commission Delegated Regulation (EU) 2016/958, and Section 206 of the Investment Advisers Act of 1940 require every person who produces or disseminates investment recommendations to disclose their conflicts of interest and to act honestly.

The Purple Compounder personally holds positions in the same stocks on which signals are published. For every signal — without exception — it is stated whether the signal publisher personally holds a position in the relevant instrument at the time of publication.

Current Position Disclosure (July 6, 2026):

NEM — ✅ Publisher holds position
LLY — ✅ Publisher holds position
AVGO — ✅ Publisher holds position
UTHR — ✅ Publisher holds position

I buy what I publish. I consider that an advantage, not a problem. But you are free to judge that for yourself, with full information.

Risk Warning

Investing in stocks and other financial instruments involves risk. You may lose part of your invested capital — or all of it. Past returns are not a reliable indicator of future results. The signals are purely informational. You make your own decisions, with your own money. When in doubt, consult a licensed investment adviser or your bank.

Your Choice

By subscribing, you confirm that you understand what you are purchasing: market information, not personalised advice. You decide independently whether and how you act on the basis of the published signals. That is your right — and your responsibility.

Legal References

Ce que vous recevez ici — et ce que vous ne recevez pas

Il s'agit d'un abonnement à des signaux. Pas de conseils. Cette distinction n'est pas seulement sémantique — elle est juridiquement déterminante, et c'est précisément la raison pour laquelle ce service opère légalement sans aucune licence de la FSMA ou de tout autre régulateur financier.

Chaque signal publié par The Purple Compounder est envoyé simultanément à tous les abonnés. Identique. Sans aucune adaptation à votre situation financière personnelle, votre profil de risque, votre horizon d'investissement ou vos objectifs financiers. Ce n'est pas une limitation. C'est la conception même du service.

La base juridique

🇧🇪 Droit belge et droit de l'Union européenne

Les conseils en investissement — au sens de la Directive européenne 2014/65/UE (MiFID II), art. 4(1)(4), et de la Loi belge du 25 octobre 2016 relative à l'accès à l'activité de prestation de services d'investissement (M.B. 18 novembre 2016) — sont légalement définis comme une recommandation personnalisée adressée à un client spécifique, tenant compte de ses circonstances individuelles.

Ce n'est pas le cas ici. Les signaux distribués simultanément via un canal de distribution à tous les abonnés ne constituent pas une recommandation personnelle au sens de l'art. 9(2) du Règlement délégué (UE) 2017/565. Ils ne relèvent donc pas de l'obligation d'agrément. The Purple Compounder n'est pas une entreprise d'investissement, ni un conseiller en investissement, ni un gestionnaire de portefeuille au sens de la législation applicable.

Aucune licence FSMA n'est requise. Ce n'est pas une opinion — cela découle directement de la loi.

🇺🇸 Droit fédéral américain — Investment Advisers Act of 1940

Les signaux publiés par The Purple Compounder sont exemptés d'enregistrement auprès de la SEC en vertu de la Section 202(a)(11)(D) de l'Investment Advisers Act of 1940 (15 U.S.C. § 80b-2(a)(11)(D)), la dite « publisher's exemption ». Les signaux sont publiés de manière générique et simultanée à tous les abonnés, sans personnalisation, et constituent une publication financière de bonne foi, de circulation générale et régulière, telle que confirmée par la Cour suprême des États-Unis dans l'affaire Lowe v. SEC, 472 U.S. 181 (1985).

The Purple Compounder n'est pas enregistré auprès de la SEC en tant que conseiller en investissement, n'est pas un courtier-négociant enregistré, et ne fournit pas de conseils personnalisés en investissement. Rien dans cet abonnement ne constitue un conseil en investissement au sens du droit fédéral ou étatique américain sur les valeurs mobilières. Les abonnés aux États-Unis sont seuls responsables de leurs obligations légales locales.

Intérêts et transparence (MAR art. 20)

Le Règlement (UE) n° 596/2014 (MAR), art. 20, le Règlement délégué (UE) 2016/958 qui l'accompagne, et la Section 206 de l'Investment Advisers Act of 1940 obligent toute personne produisant ou diffusant des recommandations d'investissement à divulguer ses conflits d'intérêts et à agir honnêtement.

The Purple Compounder détient personnellement des positions dans les mêmes actions sur lesquelles des signaux sont publiés. Pour chaque signal — sans exception — il est indiqué si l'auteur du signal détient lui-même une position dans l'instrument concerné au moment de la publication.

Divulgation des positions actuelles (6 juillet 2026) :

NEM — ✅ L'éditeur détient une position
LLY — ✅ L'éditeur détient une position
AVGO — ✅ L'éditeur détient une position
UTHR — ✅ L'éditeur détient une position

J'achète ce que je publie. Je considère cela comme un avantage, pas un problème. Mais vous êtes libre d'en juger vous-même, avec une information complète.

Avertissement sur les risques

Investir dans des actions et autres instruments financiers comporte des risques. Vous pouvez perdre une partie de votre capital investi — ou la totalité. Les performances passées ne constituent pas un indicateur fiable des résultats futurs. Les signaux sont purement informatifs. Vous prenez vos propres décisions, avec votre propre argent. En cas de doute, consultez un conseiller en investissement agréé ou votre banque.

Votre choix

En vous abonnant, vous confirmez que vous comprenez ce que vous achetez : des informations de marché, et non des conseils personnalisés. Vous décidez de manière indépendante si et comment vous agissez sur la base des signaux publiés. C'est votre droit — et votre responsabilité.

Références juridiques